文献速递流行病学与生物统计基础与转化研究

PHQ-9、PHQ-8与PHQ-2最小可检测变化的个体患者数据荟萃分析

Minimal detectable change of the Patient Health Questionnaire-9, Patient Health Questionnaire-8, and Patient Health Questionnaire-2: individual patient data meta-analysis.
PubMed 文献 · BMJ · 2026-07-23

该研究基于个体患者数据荟萃分析,纳入非精神科场所的成年参与者,估计PHQ-9、PHQ-8和PHQ-2的最小可检测变化(MDC)。PHQ-9的MDC95为5.72分(95%CI 5.54-5.90),PHQ-8为5.51分(95%CI 5.33-5.68),PHQ-2为2.26分(95%CI 2.15-2.37)。作者认为在一般实践中PHQ-9约6分差异可作为适宜MDC阈值,专科精神卫生可考虑更高阈值。

要点

  • PHQ-9的MDC95为5.72分,一般实践可采用约6分作为阈值。
  • PHQ-8的MDC95为5.51分,PHQ-2的MDC95为2.26分。
  • 住院医疗环境中PHQ-9的MDC95最高,为6.48分。

核心结论

  • 基于汇总估计,PHQ-9约6分差异可能是普通实践中合适的MDC阈值,专科精神卫生可偏好更高阈值。
  • MDC67或MDC90阈值对变化发生的确定性较低,使用预测区间上限则确定性更高但更可能漏判变化。

研究设计与样本

  • 个体患者数据荟萃分析,检索Medline、PsycInfo和Web of Science(2000年1月1日至2018年5月9日)。
  • 纳入年龄≥18岁、非精神科场所招募且非因寻求精神卫生服务而招募的数据集,需在实施PHQ后两周内进行结构化访谈分类。
  • 参与者平均年龄49岁(标准差17),60%为女性,10%患有重性抑郁(各研究范围1-57%)。

主要发现

  • PHQ-9的MDC95为5.72分(95%CI 5.54-5.90,95%PI 4.00-7.44)。
  • PHQ-8的MDC95为5.51分(95%CI 5.33-5.68,95%PI 3.87-7.15)。
  • PHQ-2的MDC95为2.26分(95%CI 2.15-2.37,95%PI 1.20-3.32)。
  • PHQ-9的MDC95在住院医疗环境中最高,为6.48分(95%CI 6.05-6.92)。
  • PHQ-9的MDC95随重性抑郁参与者比例每增加10%而增加0.40分(95%CI 0.25-0.55),性别和年龄关联极小或无。

关键数值与推荐

  • PHQ-9的MDC95为5.72分(95%CI 5.54-5.90),MDC90和MDC67原文未报告具体数值。
  • PHQ-8的MDC95为5.51分(95%CI 5.33-5.68),PHQ-2的MDC95为2.26分(95%CI 2.15-2.37)。
  • 住院医疗环境中PHQ-9的MDC95为6.48分(95%CI 6.05-6.92)。
  • 重性抑郁比例每增加10%,PHQ-9的MDC95增加0.40分(95%CI 0.25-0.55)。

临床怎么用

  • 在普通实践中,PHQ-9评分变化达到约6分可视为超出测量误差的可靠变化。
  • 专科精神卫生环境中可考虑采用高于6分的MDC阈值。
  • 使用MDC67或MDC90阈值时,对变化真实性的确定性较低。

局限性

  • 研究纳入非精神科场所参与者,未因寻求精神卫生服务而招募,外推至专科人群需谨慎。
  • 各研究重性抑郁比例差异较大(1-57%),可能影响MDC估计的异质性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To estimate the minimal detectable change (MDC) for the Patient Health Questionnaire-9 (PHQ-9) and its eight item (PHQ-8) and two item (PHQ-2) versions including differences by participant and study characteristics. DESIGN: Individual participant data meta-analysis. DATA SOURCES: Medline, Medline In-Process and other non-indexed citations, PsycInfo, and Web of Science, 1 January 2000 to 9 May 2018. ELIGIBILITY CRITERIA FOR SELECTING STUDIES: Datasets from articles in any language if participants were aged ≥18 years, were recruited from any non-psychiatric setting, and were not recruited because they were seeking mental healthcare. Eligible datasets had a classification for major depressive disorder or major depressive episode based on a validated semi-structured or fully structured interview conducted within two weeks of administering the PHQ-9, PHQ-8, or PHQ-2. RESULTS: Pooled MDCs across studies were estimated for the PHQ-9, PHQ-8, and PHQ-2 with random effects meta-analysis for 95% (MDC95), 90% (MDC90), and 67% (MDC67) confidence that change beyond measurement error occurred. PHQ-9, PHQ-8, and PHQ-2 analyses included 42 548 participants (94 studies), 42 592 participants (94 studies), and 44 085 participants (98 studies), respectively. Mean participant age was 49 years (standard deviation 17), and 60% of participants were women. Overall, 10% of participants had major depression (range 1-57% across studies). MDC95 was 5.72 points (95% confidence interval (CI) 5.54 to 5.90, 95% prediction interval (PI) 4.00 to 7.44) for the PHQ-9, 5.51 points (95% CI 5.33 to 5.68, 95% PI 3.87 to 7.15) for the PHQ-8, and 2.26 points (95% CI 2.15 to 2.37, 95% PI 1.20 to 3.32) for the PHQ-2. For the PHQ-9, MDC95 was highest in inpatient healthcare settings at 6.48 (95% CI 6.05 to 6.92) points. MDC95 for the PHQ-9 increased by 0.40 (95% CI 0.25 to 0.55) points for each 10% increase in the proportion of participants with major depression. Sex and age had minimal or no association. Subgroup and meta-regression findings were similar for the PHQ-8 and PHQ-2. CONCLUSIONS: Based on the pooled estimate, a six point difference on the PHQ-9, the PHQ version most used in clinical practice, could be an appropriate MDC threshold in general practice. A higher threshold may be preferred in specialty mental healthcare. MDC67 or MDC90 thresholds would provide less certainty that change has occurred. Alternative strategies, such as using the upper end of a prediction interval, would provide more certainty but a greater likelihood of not recognising change. STUDY REGISTRATION: PROSPERO CRD42014010673.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Wang Y, Wu Y, González-Domínguez NP, et al. Minimal detectable change of the Patient Health Questionnaire-9, Patient Health Questionnaire-8, and Patient Health Questionnaire-2: individual patient data meta-analysis. BMJ. 2026. PMID: 42492960. doi:10.1136/bmj-2026-100119

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。